Guimu Guo

#18 Daoshan Road
Fuzhou, 350001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Dipyridamole-associated pulmonary edema: discovery of a new potential adverse reaction signal based on the FAERS database.

Dipyridamole-associated pulmonary edema: discovery of a new potential adverse reaction signal based on the FAERS database.

Journal: Expert opinion on drug safety

Published: January 21, 2026

Mining safety signals of PD-1/PD-L1 inhibitor-related adrenal insufficiency: a study based on the FAERS database.

Mining safety signals of PD-1/PD-L1 inhibitor-related adrenal insufficiency: a study based on the FAERS database.

Journal: Journal of endocrinological investigation

Published: October 10, 2025

Pharmacokinetic prediction and dosage adjustment of enoxaparin administration in pregnant women with renal insufficiency: A FAERS-PBPK modeling study.

Pharmacokinetic prediction and dosage adjustment of enoxaparin administration in pregnant women with renal insufficiency: A FAERS-PBPK modeling study.

Journal: Journal of pharmaceutical sciences

Published: August 05, 2025

Venous thromboembolism events associated with tofacitinib in rheumatoid arthritis patients: a real-world study from FAERS database.

Venous thromboembolism events associated with tofacitinib in rheumatoid arthritis patients: a real-world study from FAERS database.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: July 30, 2025

Argatroban-Associated Adverse Events: An Analysis Based on FDA Adverse Event Reporting System (FAERS).

Argatroban-Associated Adverse Events: An Analysis Based on FDA Adverse Event Reporting System (FAERS).

Journal: Cardiovascular toxicology

Published: June 19, 2025

A pharmacovigilance study of daptomycin use in infants under 1 year old based on the FDA adverse event reporting system.

A pharmacovigilance study of daptomycin use in infants under 1 year old based on the FDA adverse event reporting system.

Journal: Scientific reports

Published: May 28, 2025

Signal mining for non-bleeding adverse event in novel oral anticoagulants: a pharmacovigilance study based on FAERS database.

Signal mining for non-bleeding adverse event in novel oral anticoagulants: a pharmacovigilance study based on FAERS database.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: May 09, 2025

Physiologically based pharmacokinetic model of sodium-glucose cotransporter 2 inhibitors predicted pharmacokinetics and pharmacodynamics to explore dosage regimen for patients with type 2 diabetes mellitus and renal insufficiency.

Physiologically based pharmacokinetic model of sodium-glucose cotransporter 2 inhibitors predicted pharmacokinetics and pharmacodynamics to explore dosage regimen for patients with type 2 diabetes mellitus and renal insufficiency.

Journal: Frontiers in pharmacology

Published: October 31, 2024

Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of tacrolimus in pregnant women with infection disease.

Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of tacrolimus in pregnant women with infection disease.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: August 28, 2024

Physiologically-based pharmacokinetic modeling to predict the exposure and to assess pharmacodynamics of daptomycin in infants within 1 year old.

Physiologically-based pharmacokinetic modeling to predict the exposure and to assess pharmacodynamics of daptomycin in infants within 1 year old.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: August 04, 2024

Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of Ustekinumab in pediatric patients with inflammatory bowel disease.

Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of Ustekinumab in pediatric patients with inflammatory bowel disease.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: February 01, 2024

Physiologically-Based Pharmacokinetic Modeling of Anti-Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Patients to Predict the Withdrawal Time in Pregnancy and Vaccine Time in Infants.

Physiologically-Based Pharmacokinetic Modeling of Anti-Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Patients to Predict the Withdrawal Time in Pregnancy and Vaccine Time in Infants.

Journal: Clinical pharmacology and therapeutics

Published: April 12, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026